2026-03-25 12:44:39

$ENLV earnings are out and the numbers are striking: $1.23B net profit alongside $25.48 EPS.

That’s a significant jump on paper, especially considering the company’s dual focus on Allocetra immunotherapy and their treasury strategy.
Definitely one to watch how the market digests this. @Enlivex

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes